The clinical trial, known as CRUSADERS, is focused on critically ill patients who are in the Intensive Care Unit (ICU). The study aims to explore the effects of reducing the amount of sodium chloride in the fluids given to these patients. Sodium chloride is commonly known as salt, and it is often found in the fluids used for medical treatments. The trial will compare different fluid treatments to see if lowering the salt content can lead to better outcomes for patients, such as improved survival rates and reduced need for support for breathing and kidney function.
Several types of fluid solutions will be used in the study. These include a solution with sodium chloride alone, a combination of sodium chloride and glucose monohydrate (a form of sugar), a solution with just glucose monohydrate, and a more complex solution called Plasmalyte A, which contains a mix of substances like magnesium chloride hexahydrate, potassium chloride, sodium acetate trihydrate, and sodium gluconate. These solutions are given to patients through an intravenous (IV) line, which means they are delivered directly into the bloodstream.
The purpose of the study is to determine if reducing the salt content in these fluids can improve patient outcomes. The trial will monitor various health indicators over a period of time, including the number of days patients are alive without needing life support, as well as occurrences of conditions like low or high sodium levels, fluid retention, and kidney injury. The study will also track the use of mechanical ventilation and the overall length of stay in the ICU. The trial is expected to continue until 2028, with the goal of providing valuable insights into the best fluid management strategies for critically ill patients.



Belgium